GGrantIndex
Sort

82,697 grants matching vaccine development

Specific Pathogen Free 18 Baboon Research Resource (SPF18BRR)

$1,274,599
William D Hopkins · University Of Tx Md Anderson Can Ctr · P40 · FY2025 · OD

Specific Pathogen Free 18 Baboon Research Resource (SPF18BRR)

$1,274,599
Joe H. Simmons · University Of Tx Md Anderson Can Ctr · P40 · FY2024 · OD

The "Dynamics of the immune responses to repeat influenza vaccination exposures" (DRIVE) Study

$1,274,523
Sarah Cobey · University Of Chicago · U01 · FY2024 · AI

Advanced Development of a Multivalent Vaccine Candidate for Filovirus and Lassa Fever

$1,274,067
Jeffrey Meshulam · Profectus Biosciences, Inc. · N01 · FY2019 · AI

The Miami Center for AIDS Research

$1,273,977
Savita Pahwa · University Of Miami School Of Medicine · P30 · FY2016 · AI

Cornell Clinical Trials Unit

$1,273,956
Roy M Gulick · Weill Medical Coll Of Cornell Univ · UM1 · FY2013 · AI

T Cell Immune Responses To HIV And Other Pathogens

$1,273,880
Richard A Koup · National Institute Of Allergy And Infectious Diseases · ZIA · FY2011 · AI

Tfh and B cells in HIV/SIV pathogenesis and vaccination

$1,273,880
Richard A Koup · National Institute Of Allergy And Infectious Diseases · ZIA · FY2014 · AI

Tfh and B cells in HIV/SIV pathogenesis and vaccination

$1,273,880
Richard A Koup · National Institute Of Allergy And Infectious Diseases · ZIA · FY2015 · AI

T Cell Immune Responses To HIV And Other Pathogens

$1,273,880
Richard A Koup · National Institute Of Allergy And Infectious Diseases · ZIA · FY2012 · AI

HIV/SIV Replication In Vivo

$1,273,878
Richard A Koup · National Institute Of Allergy And Infectious Diseases · ZIA · FY2014 · AI

HIV/SIV Replication In Vivo

$1,273,878
Richard A Koup · National Institute Of Allergy And Infectious Diseases · ZIA · FY2013 · AI

HIV/SIV Replication In Vivo

$1,273,878
Richard A Koup · National Institute Of Allergy And Infectious Diseases · ZIA · FY2015 · AI

Malaria parasite and vector genomics: transmission, pathology, and therapeutics

$1,273,577
Daniel E Neafsey · Broad Institute, Inc. · U19 · FY2015 · AI

Harnessing B cells for TB vaccine development to improve therapy of TB and TB-HIV coinfection

$1,273,323
Martin Alfons Gengenbacher · Hackensack University Medical Center · R01 · FY2024 · AI

Administrative Core

$1,273,196
David Mitchell Smith · University Of California, San Diego · P30 · FY2022 · AI

Wirelessly controlled BSL3 vivarium system for automated microdosing in studies of infectious diseases

$1,273,102
Tuan Q Hoang · Fluid Synchrony, Llc · R44 · FY2021 · OD

CHEMOKINE ADJUVANTS FOR BIOTHREAT PATHOGEN VACCINES

$1,273,008
Chemocentryx, Inc. · U19 · FY2003 · AI

Vaccine Research and Development for Endemic, Emerging, and Resurgent Viruses

$1,272,981
Masaru Kanekiyo · National Institute Of Allergy And Infectious Diseases · ZIA · FY2024 · AI

Animal Medicine COVID Support

$1,272,902
Ruth Woodward · National Institute Of Allergy And Infectious Diseases · ZIG · FY2022 · AI

Synthetic Vaccine Against Human Pathogenic Bacteria

$1,272,803
Vince Pozsgay · Child Health And Human Development · Z01 · FY2007 · HD

Human Respiratory Syncytial Virus Biology And Vaccine Development

$1,272,696
Peter Leon Collins · National Institute Of Allergy And Infectious Diseases · ZIA · FY2011 · AI

IND-enabling Preclinical Studies on Anti-Tau AD Vaccine for Phase 1 Trial

$1,272,333
Michael G Agadjanyan · Institute For Molecular Medicine · U01 · FY2020 · AG

Project 1: Development of Nucleoside-Modified mRNAs Encoding Sequential HIV-1 Envelopes for Initiation of V3-glycan Neutralizing Antibody Lineages

$1,272,291
Barton F Haynes · Duke University · U19 · FY2018 · AI

Advanced Development of a Multivalent Vaccine Candidate for Filovirus and Lassa Fever

$1,272,259
Matthias Schnell · Thomas Jefferson University · N01 · FY2021 · AI